ArticleInfection and immunity2026
Sero-epidemiological and functional evaluation of IgG specific for a cysteine protease inhibitor of
Jyoti Bhardwaj, Erik L Gaskin, Prasida Holla, Oscar De Los Santos, Safiatou Doumbo, Kassoum Kayentao, Aissata Ongoiba, Boubacar Traore, Peter D Crompton, Tuan M Tran
Abstract read
In one paragraphArticle in Infection and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Jyoti BhardwajDivision of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0001-6578-8423 Erik L GaskinDivision of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Prasida HollaDivision of Pediatric Infectious Diseases and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0001-5479-668X Oscar De Los SantosDivision of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Safiatou DoumboMali International Center of Excellence in Research, University of Sciences, Technique and Technology of Bamako, Bamako, Mali.
Kassoum KayentaoMali International Center of Excellence in Research, University of Sciences, Technique and Technology of Bamako, Bamako, Mali.
Aissata OngoibaMali International Center of Excellence in Research, University of Sciences, Technique and Technology of Bamako, Bamako, Mali.
Boubacar TraoreMali International Center of Excellence in Research, University of Sciences, Technique and Technology of Bamako, Bamako, Mali.
Peter D CromptonMalaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.ORCID 0000-0001-5629-0412 Tuan M TranDivision of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-1928-861X Funding
Defining clinical and sterile immunity to Plasmodium falciparum infection using systems biology approachesK08AI125682 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI TRAN, TUAN MANH · 2017 to 2021
$926kValidation and characterization of antibody responses to Plasmodium falciparum antigens identified by protein array screeningR03AI159780 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI TRAN, TUAN MANH · 2021 to 2022
$159kNIAID NIH HHS K08 AI125682NIAID NIH HHS R03 AI159780NIH HHS 5K08AI125682NIH HHS 5R03AI159780Ralph W. and Grace M. Showalter Research Trust Fund
6 · The paper itselfAbstract
Recently approved malaria pre-erythrocytic vaccines are important public health tools for the reduction of malaria morbidity and mortality. However, these vaccines have shown reduced protection in some of the most vulnerable age groups, require multiple dosing, and have the potential for parasite escape. These limitations have motivated the development of vaccines targeting multiple stages of the parasite life cycle. To ensure a robust pipeline, pre-clinical evaluation of additional malaria vaccine candidate antigens remains a key priority. The
Indexed as
Antibodies, ProtozoanCysteine Proteinase InhibitorsImmunoglobulin GMalaria, FalciparumPlasmodium falciparumHumansSeroepidemiologic StudiesAntibodies, ProtozoanCysteine Proteinase InhibitorsImmunoglobulin GfalstatinIgG antibodiesinhibitor of cysteine proteaseslongitudinal studymalaria riskPlasmodium falciparumprospective cohort
Identifiers
PMID42550035
PMCPMC13552103
What OpenQuestion holds
Textmetadata
Read underepoch 390